Type 2 Inflammation and Asthma in Children: A Narrative Review
Top Cited Papers
Open Access
- 13 June 2024
- journal article
- review article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (9) , 2310-2324
Abstract
No abstract availableKeywords
Funding Information
- Regeneron Pharmaceuticals Inc
- Sanofi US
This publication has 126 references indexed in Scilit:
- Understanding the role of long-acting muscarinic antagonists in asthma treatmentAnnals of Allergy, Asthma & Immunology, 2022
- Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe AsthmaJAMA, 2021
- Association of Oral Corticosteroid Bursts With Severe Adverse Events in ChildrenJAMA Pediatrics, 2021
- Japanese guidelines for childhood asthma 2020Allergology International, 2020
- Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on BenralizumabDrug Safety, 2020
- Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic AsthmaAdvances in Therapy, 2019
- ‘Real-life’ experience in asthmatic children treated with omalizumab up to six-years follow-upAllergologia et Immunopathologia, 2019
- Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: A systematic reviewPediatric Pulmonology, 2018
- Understanding Asthma Phenotypes, Endotypes, and Mechanisms of DiseaseClinical Reviews in Allergy & Immunology, 2018
- Association Between Inhaled Corticosteroid Use and Bone Fracture in Children With AsthmaJAMA Pediatrics, 2018